XML 43 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Balance Sheets - USD ($)
Sep. 30, 2015
Dec. 31, 2014
Current Assets    
Cash and cash equivalents $ 24,042,699 $ 19,174,061
Marketable securities 5,349,396 7,080,053
Accounts receivable, net of allowance for doubtful accounts of $381,588 and $385,362 at September 30, 2015 and December 31, 2014, respectively 2,299,817 3,111,274
Deferred costs 3,348,619 2,566,989
Prepaid expenses and other current assets 3,441,156 4,349,167
Total current assets 38,481,687 36,281,544
Property, plant and equipment, net 17,095,395 15,960,731
Goodwill 25,209,336 25,209,336
Intangible assets, net 37,706,498 47,560,406
Other assets 1,209,632 1,263,375
Total assets 119,702,548 126,275,392
Current Liabilities    
Accounts payable 2,467,049 5,661,173
Accrued liabilities 8,011,205 4,322,901
Long-term debt, current 2,751,425 1,109,612
Notes payable, current 1,012,189 816,776
Unearned revenues 5,498,074 4,334,120
Total current liabilities 19,739,942 16,244,582
Long-term Liabilities    
Deferred income taxes 14,566,093 18,176,190
Notes payable 814,062 825,897
Long-term debt 12,248,575 13,890,388
Acquisition-related contingent consideration 13,880,000 18,260,000
Other long-term liabilities 3,457,457 804,546
Total liabilities $ 64,706,129 $ 68,201,603
Commitments and Contingencies
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 0.01 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2015 and December 31, 2014 $ 100 $ 100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 55,497,240 and 36,783,857 shares, at September 30, 2015 and December 31, 2014, respectively 55,497 36,784
Additional paid-in capital 395,014,267 350,428,903
Treasury stock, at cost (705,742) (705,742)
Accumulated deficit (338,935,644) (291,246,538)
Accumulated other comprehensive income 878 1,329
Total Caladrius Biosciences, Inc. stockholders' equity 55,429,356 58,514,836
Noncontrolling interests (432,937) (441,047)
Total equity 54,996,419 58,073,789
Liabilities and Equity, Total $ 119,702,548 $ 126,275,392